Small-vessel vasculitis, N Engl J Med, vol.337, pp.1512-1535, 1997. ,
2012 revised international chapel hill consensus conference nomenclature of vasculitides, Arthritis Rheum, vol.65, pp.1-11, 2013. ,
Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients, Arthritis Rheum, vol.42, pp.421-451, 1999. ,
ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis, Am J Med, vol.120, pp.9-14, 2007. ,
ANCA glomerulonephritis and vasculitis, Clin J Am Soc Nephrol, vol.12, pp.1680-91, 2017. ,
Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA): minor target antigens in ANCA-associated vasculitis, Clin Exp Immunol, vol.150, pp.42-50, 2007. ,
With complements from ANCA mice, J Am Soc Nephrol, vol.25, pp.207-216, 2014. ,
Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis, Am J Pathol, vol.135, issue.5, pp.921-951, 1989. ,
Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis, J Clin Immunol, vol.29, pp.282-91, 2009. ,
Clinical and histological outcome predictors in renal limited pauci-immune crescentic glomerulonephritis: a single centre experience, Int J Immunopathol Pharmacol, vol.25, pp.287-92, 2012. ,
Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro, Proc Natl Acad Sci, vol.87, pp.4115-4124, 1990. ,
Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha, Am J Pathol, vol.167, pp.47-58, 2005. ,
Effect of tumor necrosis factorinduced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies, Blood, vol.86, pp.3189-95, 1995. ,
A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis, J Am Soc Nephrol, vol.10, pp.1224-1257, 1999. ,
Increased membrane expression of proteinase 3 during neutrophil adhesion in the presence of anti proteinase 3 antibodies, J Am Soc Nephrol, vol.18, pp.2330-2339, 2007. ,
Antineutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa, J Immunol, vol.153, pp.1271-80, 1994. ,
Phagocyte NADPH oxidase restrains the inflammasome in ANCA-induced GN, J Am Soc Nephrol, vol.26, pp.411-435, 2015. ,
NETosis: at the crossroads of rheumatoid arthritis, lupus, and vasculitis, Joint Bone Spine, vol.84, pp.255-62, 2017. ,
Netting neutrophils in autoimmune small-vessel vasculitis, Nat Med, vol.15, pp.623-628, 2009. ,
Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity, Blood, vol.120, pp.3007-3025, 2012. ,
Neutrophil extracellular traps in ANCA-associated vasculitis, Front Immunol, vol.7, 2016. ,
Immune stimulatory effects of neutrophil extracellular traps in granulomatosis with polyangiitis, Clin Exp Rheumatol, vol.35, pp.33-42, 2017. ,
, Autoimmunity Reviews, vol.19, p.102424, 2020.
Interaction of proteinase 3 with its associated partners: implications in the pathogenesis of Wegener's granulomatosis, Curr Opin Rheumatol, vol.22, pp.1-7, 2010. ,
C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis, J Am Soc Nephrol, vol.20, pp.289-98, 2009. ,
C5a-induced expression of P-selectin in endothelial cells, J Clin Invest, vol.94, pp.1147-55, 1994. ,
Complement c3a and c5a induce different signal transduction cascades in endothelial cells, J Immunol, vol.169, pp.2102-2112, 2002. ,
Current and emerging treatment options fo ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents, Drug Des Devel Ther, p.333, 2015. ,
B cell therapy in ANCA-associated vasculitis: current and emerging treatment options, Nat Rev Rheumatol, vol.14, pp.580-91, 2018. ,
T-helper cells as new players in ANCA-associated vasculitides, Arthritis Res Ther, vol.13, p.236, 2011. ,
Complement, a target for therapy in inflammatory and degenerative diseases, Nat Rev Drug Discov, vol.14, pp.857-77, 2015. ,
The complement system as a potential therapeutic target in rheumatic disease, Nat Rev Rheumatol, vol.13, pp.538-585, 2017. ,
The central role of the alternative complement pathway in human disease, J Immunol, vol.176, pp.1305-1315, 2006. ,
The complement system in systemic autoimmune disease, J Autoimmun, vol.34, pp.276-86, 2010. ,
Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice, Kidney Int, vol.71, pp.646-54, 2007. ,
Molecules great and small: the complement system, Clin J Am Soc Nephrol, vol.10, pp.1636-50, 2015. ,
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice, J Clin Invest, vol.110, pp.955-63, 2002. ,
Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo, Blood, vol.104, pp.1411-1419, 2004. ,
Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes, Ann Rheum Dis, vol.66, pp.1679-82, 2007. ,
Animal models of antineutrophil cytoplasm antibody-associated vasculitis, Curr Opin Rheumatol, vol.24, pp.1-7, 2012. ,
Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo, Blood, vol.106, pp.2050-2058, 2005. ,
Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies, Am J Pathol, vol.170, pp.52-64, 2007. ,
Activation of complement in normal serum by hydrogen peroxide and hydrogen peroxide-related oxygen radicals produced by activated neutrophils, Clin Exp Immunol, vol.90, pp.72-80, 1992. ,
Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes, Immunobiology, vol.195, pp.80050-80057, 1996. ,
Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils, J Immunol, vol.158, pp.4444-51, 1997. ,
Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5: complement and vasculitis, J Pathol, vol.240, pp.61-71, 2016. ,
C5a Receptor (CD88) blockade protects against MPO-ANCA GN, J Am Soc Nephrol, vol.25, pp.225-256, 2014. ,
Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg, J Immunol, vol.134, pp.3325-3356, 1985. ,
C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway, Kidney Int, vol.61, pp.456-63, 2002. ,
Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis, Am J Pathol, vol.160, issue.10, pp.61133-61142, 2002. ,
Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation, Blood, vol.100, pp.1869-77, 2002. ,
The inhibition of neutrophil granule enzyme secretion and chemotaxis by pertussis toxin, J Cell Biol, vol.100, pp.1641-1647, 1985. ,
The chemotactic receptor for human C5a anaphylatoxin, Nature, vol.349, pp.614-621, 1991. ,
A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells, Mol Immunol, vol.37, pp.407-419, 2000. ,
C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity, J Immunol, vol.188, pp.4032-4074, 2012. ,
Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse, J Immunol, vol.194, pp.1841-55, 2015. ,
Encyclopedia of immunobiology, 2016. ,
C5L2, a nonsignaling C5A binding protein, Biochemistry, vol.42, pp.9406-9421, 2003. ,
An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2, J Biol Chem, vol.280, pp.39677-80, 2005. ,
The human complement fragment receptor, C5L2, is a recycling decoy receptor, Mol Immunol, vol.46, pp.1149-62, 2009. ,
The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction, J Biol Chem, vol.285, pp.7633-7677, 2010. ,
C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a, Nature, vol.446, pp.203-210, 2007. ,
Functional roles for C5a receptors in sepsis, Nat Med, vol.14, pp.551-558, 2008. ,
Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies, J Am Soc Nephrol, vol.17, pp.3355-64, 2006. ,
Complement alternative pathway acts as a positive feedback amplification of neutrophil activation, Blood, vol.117, pp.1340-1349, 2011. ,
ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation, PLoS One, vol.7, 2012. ,
Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis, Kidney Int, vol.83, pp.129-166, 2013. ,
C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Arthritis Res Ther, vol.14, 2012. ,
Association of low serum complement C3 with reduced patient and renal survival in antimyeloperoxidase-associated small-vessel vasculitis, Nephron Clin Pract, vol.126, pp.67-74, 2014. ,
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis, Clin J Am Soc Nephrol, vol.10, pp.2143-51, 2015. ,
Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis, PLoS One, vol.11, 2016. ,
Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis, Medicine (Baltimore), vol.95, 2016. ,
Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis, PLoS One, vol.13, 2018. ,
Usefulness of complement split product, Bb, as a clinical marker for disease activity of lupus nephritis, Fukushima J Med Sci, vol.52, pp.103-112, 2006. ,
, Autoimmunity Reviews, vol.19, p.102424, 2020.
, alternative pathway in the early complement activation following major trauma, Shock, vol.28, pp.29-34, 2007.
Specificity of EIA immunoassay for complement factor Bb testing, Clin Lab, vol.57, pp.225-233, 2011. ,
Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN ,
, Clin J Am Soc Nephrol, vol.8, pp.1884-91, 2013.
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution, J Exp Med, vol.146, pp.257-70, 1977. ,
Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11, J Immunol, vol.163, pp.3957-62, 1999. ,
Atypical hemolytic-uremic syndrome, N Engl J Med, vol.361, pp.1676-87, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01793663
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney Int, vol.82, pp.454-64, 2012. ,
Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis, Arthritis Res Ther, vol.17, 2015. ,
Myeloperoxidase influences the complement regulatory activity of complement factor H, Rheumatology (Oxford, 2018. ,
Mayo clinic/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN, J Am Soc Nephrol, vol.27, pp.1278-87, 2016. ,
Pathogenesis of antineutrophil cytoplasmic autoantibodymediated disease, Nat Rev Rheumatol, vol.10, pp.463-73, 2014. ,
Cutaneous manifestations of Wegener granulomatosis, Arch Dermatol, vol.113, p.175, 1977. ,
Review article: pathogenic role of complement activation in anti-neutrophil cytoplasmic auto-antibody-associated vasculitis, Nephrology, vol.14, pp.16-25, 2009. ,
Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases, Kidney Int, vol.65, pp.2145-52, 2004. ,
Complement in ANCA-associated glomerulonephritis, Nephrol Dial Transplant, vol.32, pp.1302-1315, 2017. ,
Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis, Am J Pathol, vol.142, pp.179-87, 1993. ,
Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis, Nephrol Dial Transplant, vol.24, pp.1247-52, 2008. ,
Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis, J Clin Immunol, vol.30, pp.144-56, 2010. ,
C4d as a diagnostic tool in proliferative GN, J Am Soc Nephrol, vol.26, pp.2852-2861, 2015. ,
Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis, Nephrol Dial Transplant, vol.32, pp.139-184, 2017. ,
Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis, Am J Kidney Dis, vol.60, pp.126-158, 2012. ,
Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN), J Immunol, vol.135, pp.2063-2071, 1985. ,
The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg 74, J Biol Chem, vol.277, pp.7165-7174, 2002. ,
Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: complement regulatory proteins in AAV, Clin Exp Immunol, vol.191, pp.116-140, 2018. ,
New pathophysiological insights and treatment of ANCA-associated vasculitis, Kidney Int, vol.79, pp.599-612, 2011. ,
Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study, PLoS One, vol.11, 2016. ,
Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis, J Am Soc Nephrol, vol.28, pp.2756-67, 2017. ,
A Randomized clinical trial of CCX168, an orally administered C5aR inhibitor for treatment of patients with ANCA-associated vasculitis (abstract), Arthritis Rheumatol, vol.68, p.2016, 2016. ,
The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study, BMC Med Res Methodol, vol.1, 2001. ,
Biostatistics for biomedical research, 2016. ,
Comparisons against baseline within randomised groups are often used and can be highly misleading, Trials, vol.12, 2011. ,
Phase 3 clinical trial of CCX168 (avacopan) in patients with ANCA-associated vasculitis (ADVOCATE) (NCT02994927), 2016. ,
Maintenance treatment of ANCA-associated vasculitides, Clin Exp Rheumatol, vol.35, pp.199-201, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01064298
Avoidance of harm from treatment for ANCA-associated vasculitis, Curr Treatm Opt Rheumatol, vol.3, pp.230-273, 2017. ,
Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis, Ann Rheum Dis, vol.69, pp.1036-1079, 2010. ,
Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease, Clin J Am Soc Nephrol, vol.7, pp.240-247, 2012. ,
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis, Rheumatology, 2018. ,
Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis, Nephrol Dial Transplant, 2018. ,
, Autoimmunity Reviews, vol.19, p.102424, 2020.